Calcified Tissue International

, Volume 94, Issue 6, pp 580–589

Incidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records Databases

  • G. Requena
  • V. Abbing-Karahagopian
  • C. Huerta
  • M. L. De Bruin
  • Y. Alvarez
  • M. Miret
  • U. Hesse
  • H. Gardarsdottir
  • P. C. Souverein
  • J. Slattery
  • C. Schneider
  • M. Rottenkolber
  • S. Schmiedl
  • M. Gil
  • M. C. H. De Groot
  • A. Bate
  • A. Ruigómez
  • L. A. García Rodríguez
  • S. Johansson
  • F. de Vries
  • D. Montero
  • R. Schlienger
  • R. Reynolds
  • O. H. Klungel
  • F. J. de Abajo
Original Research

Abstract

Hip fractures represent a major public health challenge worldwide. Multinational studies using a common methodology are scarce. We aimed to estimate the incidence rates (IRs) and trends of hip/femur fractures over the period 2003–2009 in five European countries. The study was performed using seven electronic health-care records databases (DBs) from Denmark, The Netherlands, Germany, Spain, and the United Kingdom, based on the same protocol. Yearly IRs of hip/femur fractures were calculated for the general population and for those aged ≥50 years. Trends over time were evaluated using linear regression analysis for both crude and standardized IRs. Sex- and age-standardized IRs for the UK, Netherlands, and Spanish DBs varied from 9 to 11 per 10,000 person-years for the general population and from 22 to 26 for those ≥50 years old; the German DB showed slightly higher IRs (about 13 and 30, respectively), whereas the Danish DB yielded IRs twofold higher (19 and 52, respectively). IRs increased exponentially with age in both sexes. The ratio of females to males was ≥2 for patients aged ≥70–79 years in most DBs. Statistically significant trends over time were only shown for the UK DB (CPRD) (+0.7 % per year, P < 0.01) and the Danish DB (−1.4 % per year, P < 0.01). IRs of hip/femur fractures varied greatly across European countries. With the exception of Denmark, no decreasing trend was observed over the study period.

Keywords

Hip fracture Incidence rate Electronic health-care record European country 

Supplementary material

223_2014_9850_MOESM1_ESM.pdf (475 kb)
Supplementary material 1 (PDF 474 kb)

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • G. Requena
    • 1
  • V. Abbing-Karahagopian
    • 2
  • C. Huerta
    • 3
  • M. L. De Bruin
    • 2
  • Y. Alvarez
    • 4
  • M. Miret
    • 5
  • U. Hesse
    • 6
  • H. Gardarsdottir
    • 2
    • 7
  • P. C. Souverein
    • 2
  • J. Slattery
    • 4
  • C. Schneider
    • 8
  • M. Rottenkolber
    • 9
  • S. Schmiedl
    • 10
    • 11
  • M. Gil
    • 3
  • M. C. H. De Groot
    • 2
  • A. Bate
    • 12
  • A. Ruigómez
    • 13
  • L. A. García Rodríguez
    • 13
  • S. Johansson
    • 14
  • F. de Vries
    • 2
    • 15
    • 16
  • D. Montero
    • 3
  • R. Schlienger
    • 17
  • R. Reynolds
    • 18
  • O. H. Klungel
    • 2
    • 19
  • F. J. de Abajo
    • 1
    • 20
  1. 1.Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health SciencesUniversity of AlcaláMadridSpain
  2. 2.Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical PharmacologyUtrecht UniversityUtrechtThe Netherlands
  3. 3.Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use DepartmentSpanish Agency for Medicines and Medical Devices (AEMPS)MadridSpain
  4. 4.Signal Detection and Data Analysis, Pharmacovigilance and Risk ManagementEuropean Medicines Agency (EMA)LondonUK
  5. 5.Merck KGaAGenevaSwitzerland
  6. 6.Statens Serum InstituteNational Institute for Health Data and Disease ControlCopenhagenDenmark
  7. 7.Department of Clinical Pharmacy, Division Laboratory and PharmacyUniversity Medical Center UtrechtUtrechtThe Netherlands
  8. 8.Division Clinical Pharmacy & EpidemiologyUniversity of BaselBaselSwitzerland
  9. 9.Institute for Medical Information Sciences, Epidemiology, and BiometryLudwig-Maximilians-Universitaet MünchenMunichGermany
  10. 10.Department of Clinical Pharmacology, School of Medicine, Faculty of HealthWitten/Herdecke UniversityWittenGermany
  11. 11.Philipp Klee-Institute for Clinical PharmacologyHELIOS Clinic WuppertalWuppertalGermany
  12. 12.EpidemiologyPfizer Ltd.TadworthUK
  13. 13.Spanish Center for Pharmacoepidemiological Research (CEIFE)MadridSpain
  14. 14.AstraZeneca ABMölndalSweden
  15. 15.MRC Epidemiology Resource CentreSouthampton General HospitalSouthamptonUK
  16. 16.School CAPHRIMaastricht UniversityMaastrichtThe Netherlands
  17. 17.Global Clinical EpidemiologyNovartis Pharma AGBaselSwitzerland
  18. 18.Epidemiology, Medical DivisionPfizerNew YorkUSA
  19. 19.Julius Center for Health Sciences and Primary CareUniversity Medical Center Utrecht (UMCU)UtrechtThe Netherlands
  20. 20.Clinical Pharmacology UnitUniversity Hospital Príncipe de AsturiasMadridSpain

Personalised recommendations